Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$131.79
+0.2%
$133.47
$99.71
$141.23
$228.77B0.736.17 million shs9.89 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$84.13
-0.8%
$84.51
$57.52
$117.19
$33.24B1.444.43 million shs2.35 million shs
HealthEquity, Inc. stock logo
HQY
HealthEquity
$97.67
+1.5%
$101.21
$65.01
$116.65
$8.32B0.49871,267 shs940,815 shs
Insulet Corporation stock logo
PODD
Insulet
$288.27
-0.6%
$308.58
$173.00
$329.33
$20.41B1.35719,013 shs386,894 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-0.48%-1.45%-2.95%+1.29%+27.59%
DexCom, Inc. stock logo
DXCM
DexCom
-0.64%+1.22%+3.40%+23.35%-24.98%
HealthEquity, Inc. stock logo
HQY
HealthEquity
-1.19%-6.73%-8.19%+16.60%+24.81%
Insulet Corporation stock logo
PODD
Insulet
-0.69%-2.20%-4.81%+15.66%+45.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9439 of 5 stars
2.45.04.24.52.72.52.5
DexCom, Inc. stock logo
DXCM
DexCom
4.783 of 5 stars
3.53.00.04.73.62.51.9
HealthEquity, Inc. stock logo
HQY
HealthEquity
3.0088 of 5 stars
3.51.00.00.02.22.51.9
Insulet Corporation stock logo
PODD
Insulet
4.5696 of 5 stars
3.43.00.04.92.80.81.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.76
Moderate Buy$144.339.52% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.91
Moderate Buy$99.6018.39% Upside
HealthEquity, Inc. stock logo
HQY
HealthEquity
3.00
Buy$118.5521.37% Upside
Insulet Corporation stock logo
PODD
Insulet
2.83
Moderate Buy$321.0011.35% Upside

Current Analyst Ratings Breakdown

Latest DXCM, HQY, PODD, and ABT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$130.00 ➝ $140.00
7/16/2025
DexCom, Inc. stock logo
DXCM
DexCom
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$95.00 ➝ $100.00
7/15/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$145.00 ➝ $147.00
7/15/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$127.00 ➝ $137.00
7/15/2025
DexCom, Inc. stock logo
DXCM
DexCom
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$82.00 ➝ $89.00
7/8/2025
Insulet Corporation stock logo
PODD
Insulet
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/8/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$140.00 ➝ $145.00
7/8/2025
HealthEquity, Inc. stock logo
HQY
HealthEquity
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy$115.00 ➝ $120.00
6/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$143.00
6/16/2025
DexCom, Inc. stock logo
DXCM
DexCom
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$102.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$41.95B5.47$6.60 per share19.97$27.62 per share4.77
DexCom, Inc. stock logo
DXCM
DexCom
$4.03B8.18$2.23 per share37.72$5.38 per share15.64
HealthEquity, Inc. stock logo
HQY
HealthEquity
$1.20B7.04$4.33 per share22.56$24.40 per share4.00
Insulet Corporation stock logo
PODD
Insulet
$2.07B9.79$4.41 per share65.36$17.27 per share16.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.7127.5123.002.5031.89%19.01%10.82%7/17/2025 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.3451.3834.201.8112.90%30.05%10.00%7/30/2025 (Estimated)
HealthEquity, Inc. stock logo
HQY
HealthEquity
$96.70M$1.3736.4334.391.499.80%11.01%6.77%9/2/2025 (Estimated)
Insulet Corporation stock logo
PODD
Insulet
$418.30M$5.5680.1158.002.5918.29%22.25%8.29%8/7/2025 (Confirmed)

Latest DXCM, HQY, PODD, and ABT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Insulet Corporation stock logo
PODD
Insulet
$0.9290N/AN/AN/A$612.31 millionN/A
7/30/2025Q2 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.45N/AN/AN/A$1.13 billionN/A
7/17/2025Q2 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.25N/AN/AN/A$11.01 billionN/A
6/3/2025Q1 2026
HealthEquity, Inc. stock logo
HQY
HealthEquity
$0.81$0.97+$0.16$0.61$322.25 million$330.80 million
5/8/2025Q1 2025
Insulet Corporation stock logo
PODD
Insulet
$0.81$1.02+$0.21$0.50$543.20 million$569.00 million
5/1/2025Q1 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billion
4/16/2025Q1 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.07$1.09+$0.02$0.76$10.38 billion$10.36 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.79%N/A30.61%54 Years
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
HealthEquity, Inc. stock logo
HQY
HealthEquity
N/AN/AN/AN/AN/A
Insulet Corporation stock logo
PODD
Insulet
N/AN/AN/AN/AN/A

Latest DXCM, HQY, PODD, and ABT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/13/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.73%7/15/20257/15/20258/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.26
1.78
1.27
DexCom, Inc. stock logo
DXCM
DexCom
0.55
1.50
1.32
HealthEquity, Inc. stock logo
HQY
HealthEquity
0.50
4.06
4.06
Insulet Corporation stock logo
PODD
Insulet
1.21
4.47
3.63

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
HealthEquity, Inc. stock logo
HQY
HealthEquity
99.55%
Insulet Corporation stock logo
PODD
Insulet
N/A

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
DexCom, Inc. stock logo
DXCM
DexCom
0.32%
HealthEquity, Inc. stock logo
HQY
HealthEquity
1.50%
Insulet Corporation stock logo
PODD
Insulet
0.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
10,300392.11 million390.85 millionOptionable
HealthEquity, Inc. stock logo
HQY
HealthEquity
3,12086.47 million85.18 millionOptionable
Insulet Corporation stock logo
PODD
Insulet
3,90070.38 million70.10 millionOptionable

Recent News About These Companies

Insulet hires new chief HR officer from J&J

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$131.79 +0.30 (+0.23%)
Closing price 03:59 PM Eastern
Extended Trading
$132.24 +0.45 (+0.34%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

DexCom stock logo

DexCom NASDAQ:DXCM

$84.13 -0.65 (-0.77%)
Closing price 04:00 PM Eastern
Extended Trading
$84.19 +0.06 (+0.07%)
As of 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

HealthEquity stock logo

HealthEquity NASDAQ:HQY

$97.67 +1.49 (+1.55%)
Closing price 04:00 PM Eastern
Extended Trading
$97.62 -0.05 (-0.05%)
As of 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.

Insulet stock logo

Insulet NASDAQ:PODD

$288.27 -1.72 (-0.59%)
Closing price 04:00 PM Eastern
Extended Trading
$281.27 -7.00 (-2.43%)
As of 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.